Of these fusions, 16 (including ALK, ARAF, BRAF, FGFR1, FGFR3, RET, and ROS1) and 21 (including ABL1, GNAS, JAK2, and NRG1) were classified as either related to lung cancer, or as oncogenes that have not been reported in lung cancer, respectively (Fig. 2). Here, JAK2 is linked to lung carcinoma.